Thursday, March 25, 2021 1:25:59 PM
US FDA
Bamlanivimab (bamlanivimab) Eli Lilly Canada Inc Treatment Authorized By Interim Order 2020-11-20
Veklury (remdesivir) Gilead Sciences Canada Inc Treatment Authorized 2020-07-27
Favipiravir (favipiravir) Dr Reddys Laboratories Ltd Treatment Under review Under review
Colchicine (colchicine) Footnote1 Pendopharm Division of Pharmascience Inc Treatment Under review Under review
Novavax COVID-19 Vaccine (NVX-CoV2373) Novavax Inc Vaccine Under review Under review
Bamlanivimab and etesevimab (LY-CoV555 / LY-CoV016) Eli Lilly Canada Inc Treatment Under review Under review
Casirivimab and imdevimab (casirivimab / imdevimab) Hoffmann-La Roche Limited Treatment Under review Under review
Leronlimab (leronlimab) CytoDyn, Inc. Treatment Under review Under review
Bamlanivimab (bamlanivimab) Eli Lilly Canada Inc Treatment Authorized By Interim Order 2020-11-20
Veklury (remdesivir) Gilead Sciences Canada Inc Treatment Authorized 2020-07-27
Favipiravir (favipiravir) Dr Reddys Laboratories Ltd Treatment Under review Under review
Colchicine (colchicine) Footnote1 Pendopharm Division of Pharmascience Inc Treatment Under review Under review
Novavax COVID-19 Vaccine (NVX-CoV2373) Novavax Inc Vaccine Under review Under review
Bamlanivimab and etesevimab (LY-CoV555 / LY-CoV016) Eli Lilly Canada Inc Treatment Under review Under review
Casirivimab and imdevimab (casirivimab / imdevimab) Hoffmann-La Roche Limited Treatment Under review Under review
Leronlimab (leronlimab) CytoDyn, Inc. Treatment Under review Under review
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
